We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -4.44% | 5.375 | 5.25 | 5.50 | 5.625 | 5.375 | 5.625 | 247,583 | 09:43:47 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -1.23 | 6.33M |
TIDMGDR
RNS Number : 6749C
Genedrive PLC
11 February 2020
Director/PDMR Shareholding
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Colleen Pythian, Director of Quality and Regulation and a PDMR, acquired 25,644 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 9.70p per share today.
Following these purchases, Colleen Pythian's total beneficial interest is 25,644 Ordinary Shares, 0.07% of the issued share capital of the Company.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. Details of the person discharging managerial responsibilities / person closely associated a. Name Colleen Pythian ------------------------------ ---------------------------------------- 2. Reason for the notification ------------------------------------------------------------------------ a. Position/status Director of Quality & Regulation ------------------------------ ---------------------------------------- a. Initial notification Initial notification /Amendment ------------------------------ ---------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------------ a. Name genedrive plc ------------------------------ ---------------------------------------- b. LEI 213800ZYODIRZ87Y4K14 ------------------------------ ---------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------ a. Description of Ordinary shares of 1.5 pence each the Financial instrument, type of instrument GB00B1VKB244 Identification code ------------------------------ ---------------------------------------- b. Nature of the Purchase transaction ------------------------------ ---------------------------------------- c. Price(s) and Price(s) Volume(s) volume(s) 9.70p 25,644 ------------------ ------------------------------ ---------------------------------------- d. Aggregated information * Aggregated volume N/A * Price ------------------------------ ---------------------------------------- e. Date of the transaction 2020-02-11 ------------------------------ ---------------------------------------- f. Place of the London Stock Exchange, AIM transaction ------------------------------ ----------------------------------------
For further details please contact:
genedrive plc +44 (0)161 989 0245 David Budd: CEO / Matthew Fowler: CFO Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)207 418 8900 James Steel / Oliver Jackson Stanford Capital Partners Limited (Joint Broker) +44 (0)20 3815 8880 Patrick Claridge / John Howes Walbrook PR Ltd (Media Relations & +44 (0)20 7933 8780 or Investor Relations) genedrive@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7876 Paul McManus / Anna Dunphy 741 001
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHEASAFFSKEEFA
(END) Dow Jones Newswires
February 11, 2020 11:00 ET (16:00 GMT)
1 Year Genedrive Chart |
1 Month Genedrive Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions